Danilo Tagle's Biography

Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS)

Dan Tagle is Director of the Office of Special Initiatives at NCATS where he many coordinates efforts towards development of disruptive technologies in translational research. He obtained his Ph.D. in Molecular Biology and Genetics from Wayne State University School of Medicine. He was an NIH National Research Service Award postdoctoral fellow in Human Genetics at the University of Michigan. He has served on numerous committees, advisory boards, and editorial boards. He has authored many scientific publications and has garnered numerous awards, including more recently the Roscoe O. Brady Award for Innovation and Accomplishment, and the Henry J. Heimlich Award for Innovative Medicine.

The NIH Microphysiological Systems Program: Tissue Chips for Tools for Drug Development and Precision Medicine

Tuesday, 8 November 2022 at 09:00

Add to Calendar ▼2022-11-08 09:00:002022-11-08 10:00:00Europe/LondonThe NIH Microphysiological Systems Program: Tissue Chips for Tools for Drug Development and Precision MedicineThe Space Summit 2022 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. A number of these failures can be attributed to poor predictability of human response from animal and 2D in vitro models currently being used in drug development. To address this challenges in drug development, the NIH Tissue Chips or Microphysiological Systems program is developing alternative innovative approaches for more predictive readouts of toxicity or efficacy of candidate drugs. Tissue chips are bioengineered 3D microfluidic platforms utilizing chip technology and human-derived cells and tissues that are intended to mimic tissue cytoarchitecture and functional units of human organs and systems. In addition toxicity studies in drug development, these microfabricated devices are also being used to model various human diseases for assessment of efficacy of candidate therapeutics. A more recent program is the development of “clinical trials on chips” to inform clinical trial design and implementation, and for studies in precision medicine. Presentation will provide a program update and future directions towards widespread use of tissue chip technologies in partnerships with various stakeholders.

Add to Calendar ▼2022-11-07 00:00:002022-11-08 00:00:00Europe/LondonThe Space Summit 2022The Space Summit 2022 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors